Previous studies showed that GATA2 mutations occurred in 18% to 41% of patients with CEBPAdm AML, which were obviously more common than those of CEBPAwt group or CEBPAsm group.15–17 Similarly, in our CEBPAdm cohort, GATA2 mutations occurred in 28.04% of patients. The gene discussed is GATA2; the disease is acute myeloid leukemia.